KOA Shoji HoldingsKOA SHOJI HOLDINGS CO.,LTD.9273東証プライム医薬品FY ending Jun 2026, consolidated, J-GAAP
Revenue by business segment, and the profit each one keeps.
Geographic revenue reported in annual filings
No geographic revenue breakdown was disclosed.
※ Segment figures include inter-segment sales and do not sum to the company total
X-axis: segment revenue CAGR. Y-axis: latest operating margin. Bubble size: revenue.
Bubble size represents latest revenue. Segments without a CAGR are placed at the left edge; their horizontal position is not a growth value. Color indicates positive or negative margin.
| Segment | Revenue CAGR | FY ending Jun 2022 | FY ending Jun 2023 | FY ending Jun 2024 | FY ending Jun 2025 | FY ending Jun 2026 |
|---|---|---|---|---|---|---|
| Drug Substance Sales Business | +7.8%5y | 12,84818.6% | 14,16419.3% | 13,73420.2% | 14,60122.0% | 15,71721.1% |
| Pharmaceutical Marketing Business | +5.0%5y | 7,50518.9% | 7,88919.4% | 8,40020.2% | 8,66924.7% | 8,96223.7% |
Top: revenue. Bottom: operating margin.
EDINET (FSA Japan)
有価証券報告書－第12期(2025/07/01－2026/06/30)
EDINET (FSA Japan)
有価証券報告書－第11期(2024/07/01－2025/06/30)
EDINET (FSA Japan)
有価証券報告書－第10期(2023/07/01－2024/06/30)
EDINET (FSA Japan)
訂正有価証券報告書－第9期(2022/07/01－2023/06/30)
EDINET (FSA Japan)
有価証券報告書－第8期(令和3年7月1日－令和4年6月30日)
EDINET (FSA Japan)
訂正有価証券報告書－第7期(令和2年7月1日－令和3年6月30日)
Extracted from XBRL: 49 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.